Skip to main content
SpringerLink
Log in

Schwerpunkt nichtkleinzelliges Lungenkarzinom

Strahlentherapie des nichtkleinzelligen Lungenkarzinoms

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

Die Strahlentherapie ist ein wichtiger Baustein in der lokalen Behandung des NSCLC. Dabei wurden in jüngerer Zeit erhebliche Verbesserungen im Hinblick auf Bestrahlungsplanung, Strahlanwendung und bildgeführte Überwachung erzielt. Diese helfen, die Effektivität der Therapie zu erhöhen und Toxizitäten zu reduzieren. Lesen Sie nachfolgend das Wichtigste zu Grundlagen und Anwendung der Radiotherapie, Schwerpunkt ist das NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Goldstraw P et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51

    Article  PubMed  Google Scholar 

  2. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). Cochrane Database Syst Rev. 2001;(2):CD002935

  3. Chun SG et al. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol. 2017;35(1):56–62

    Article  PubMed  Google Scholar 

  4. Atagi S et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. 2012;13(7):671–8

    Article  CAS  PubMed  Google Scholar 

  5. Eberhardt WE et al. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015;33(35):4194–201

    Article  CAS  PubMed  Google Scholar 

  6. Bradley JD et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Antonia SJ et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919–29

    Article  CAS  PubMed  Google Scholar 

  8. Shaverdian N et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Weichselbaum RR et al. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365–79

    Article  CAS  PubMed  Google Scholar 

  10. Rieber J et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group „stereotactic radiotherapy“. Lung Cancer. 2016;97:51–8

    Article  PubMed  Google Scholar 

  11. Guckenberger M et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys. 2009;74(1):47–54

    Article  PubMed  Google Scholar 

  12. Tekatli H et al. Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with „Ultracentral“ Non-Small Cell Lung Cancer. J Thorac Oncol. 2016;11(7):1081–9

    Article  PubMed  Google Scholar 

  13. Chang JY et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–7

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ball D et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019;20(4):494–503

    Article  PubMed  Google Scholar 

  15. Gomez DR et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019;37(18):1558–65

    Article  PubMed  PubMed Central  Google Scholar 

  16. Buderi SI et al. Does induction chemoradiotherapy increase survival in patients with Pancoast tumour? Interact Cardiovasc Thorac Surg. 2016;23(5):821–825

    Article  PubMed  Google Scholar 

  17. Douillard JY et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–27

    Article  CAS  PubMed  Google Scholar 

  18. Douillard JY et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys. 2008;72(3):695–701

    Article  CAS  PubMed  Google Scholar 

  19. Faivre-Finn C et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–25

    Article  PubMed  PubMed Central  Google Scholar 

  20. Slotman BJ et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385(9962):36–42

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiologische Allianz GbR, Schäferkampsallee 5–7, 20357, Hamburg, Deutschland

    Florian Würschmidt

Authors
  1. Florian Würschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florian Würschmidt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Würschmidt, F. Strahlentherapie des nichtkleinzelligen Lungenkarzinoms. Info Onkol. 22, 18–23 (2019). https://doi.org/10.1007/s15004-019-6647-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-6647-1

Search

Navigation